Source: Virtual Congress 2020 – Clinical evaluation, biomarkers and risk assessment of pulmonary hypertension
Disease area: Pulmonary vascular diseases



Rating:

Share or cite this content

Citations should be made in the following way:
S. Gaine (Dublin, Ireland), P. Escribano (Madrid, Spain), P. Biedermann (Allschwil, Switzerland), A. Muller (Allschwil, Switzerland), H. Sun (Allschwil, Switzerland), S. Söderberg (Umeå, Sweden), T. Lange (Regensburg, Germany). Risk status at selexipag initiation in pulmonary arterial hypertension (PAH): Insights from EXPOSURE. 1523

Member's Comments

No comment yet.

Related content which might interest you: Risk assessment in pulmonary arterial hypertension (PAH): Insights from the GRIPHON study Source: International Congress 2018 – Risk stratification in treatment of pulmonary arterial hypertension Year: 2018 Childhood pulmonary arterial hypertension: Insights from REVEAL Source: Annual Congress 2011 - Clinical features of pulmonary hypertension Year: 2011 Riociguat in pulmonary arterial hypertension: ERS/ESC risk assessment in PATENT Source: International Congress 2016 – Pulmonary hypertension: the clinic II Year: 2016 Risk assessment in pulmonary arterial hypertension: REVEAL vs EUROPEAN scores Source: ERS Course 2020 - Pulmonary hypertension and pulmonary vascular disease Year: 2020 Risk stratification in pulmonary arterial hypertension (PAH) Source: International Congress 2018 – New trends in the management of pulmonary hypertension Year: 2018 Long-term outcomes with initial triple oral therapy in pulmonary arterial hypertension (PAH): Insights from TRITON Source: Virtual Congress 2020 – Updated assessment and treatment of pulmonary arterial hypertension Year: 2020 Risk assessment in pulmonary arterial hypertension Source: Eur Respir Rev 2016; 25: 390-398 Year: 2016 Risk assessment in pulmonary arterial hypertension Source: Eur Respir J, 51 (3) 1702606; 10.1183/13993003.02606-2017 Year: 2018 Risk assessment in pulmonary arterial hypertension Source: Eur Respir J, 51 (3) 1800279; 10.1183/13993003.00279-2018 Year: 2018 Predictive factors of clinical worsening in functional class II patients with pulmonary arterial hypertension (PAH) in the EARLY trial of bosentan Source: Annual Congress 2008 - Medical treatment of pulmonary hypertension Year: 2008 Effect of selexipag on long-term outcomes in key subgroups of patients with pulmonary arterial hypertension (PAH): GRIPHON study results Source: International Congress 2015 – Pulmonary hypertension: new treatment insights Year: 2015 Riociguat in chronic thromboembolic pulmonary hypertension (CTEPH): ERS/ESC risk assessment in CHEST Source: International Congress 2016 – Pulmonary hypertension and chronic thromboembolic pulmonary hypertension Year: 2016 Risk stratification and medical therapy of pulmonary arterial hypertension Source: Eur Respir J, 53 (1) 1801889; 10.1183/13993003.01889-2018 Year: 2019 The effects of beta-blocker therapy on systolic and diastolic function in pulmonary arterial hypertension: A randomized controlled trial Source: International Congress 2014 – Pulmonary hypertension: improving treatment in PAH Year: 2014 LATE-BREAKING ABSTRACT: Riociguat for the treatment of pulmonary arterial hypertension (PAH): 2-year results from the PATENT-2 long-term extension Source: International Congress 2014 – New technologies and biomarkers in lung disease Year: 2014 Macitentan reduces the risk of morbidity and mortality irrespective of the presence or absence of right ventricular (RV) impairment: Results from the randomised SERAPHIN trial in pulmonary arterial hypertension (PAH) Source: International Congress 2014 – Pulmonary hypertension: improving treatment in PAH Year: 2014 Riociguat for the treatment of pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension: Real-life data from the EXPERT registry Source: International Congress 2015 – Pulmonary hypertension: new treatment insights Year: 2015 Effect of riociguat on pulmonary arterial compliance (PAC) in patients with PAH in PATENT-1 Source: International Congress 2015 – Pulmonary hypertension: novel clinical insights Year: 2015 Pregnancy and pulmonary arterial hypertension (PAH) Source: Annual Congress 2013 –Pulmonary circulation: clinical pulmonary hypertension II Year: 2013 Population pharmacokinetics of imatinib in patients with pulmonary arterial hypertension Source: Annual Congress 2013 –Pulmonary circulation: clinical treatment Year: 2013